Regulus Therapeutics reported $53.9M in Cash and Equivalent for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Alnylam Pharmaceuticals ALNY:US $ 534.08M 285.89M
AstraZeneca AZN:LN 5762M 567M
Astrazeneca AZN:US $ 5762M 567M
Biogen BIIB:US $ 1749.3M 512.1M
Celldex Therapeutics CLDX:US $ 25.29M 13.85M
Gilead Sciences GILD:US $ 4296M 1042M
GlaxoSmithKline GSK:LN 10967M 6693M
Intercept Pharmaceuticals ICPT:US $ 48.32M 36.39M
Intrexon XON:US $ 40.32M 2.6M
Lexicon Pharmaceuticals LXRX:US $ 59.52M 4.54M
Ligand Pharmaceuticals LGND:US $ 14.99M 4.53M
Merk MRK:US $ 8556M 460M
Omeros OMER:US $ 8.96M 91.84M
Regulus Therapeutics RGLS:US $ 53.9M 6.48M
Sangamo Biosciences SGMO:US $ 120.26M 58.62M
Spectrum Pharmaceuticals SPPI:US $ 78.68M 9.86M
Takeda 4502:JP Y 849695M 125354M
Vital Therapies VTL:US $ 95.71M 8.85M
YTE INCY:US $ 2256.76M 199.32M